Weight Loss

Begin your weight loss journey today!

Semaglutide

Semaglutide is a self-injectable weight loss medication that can support long-term weight management. Semaglutide is the active ingredient in the brand name drugs Ozempic and Wegovy. It is the first weight management drug for adults that has been FDA-approved since 2017 for long-term weight loss. With a once-weekly subcutaneous injection (under the skin), you can experience a decrease in appetite, reduced cravings, and an increase in fullness/satiety. Researchers found that the average weight loss is 15% of the total body weight. Semaglutide does this by targeting an area in the brain (called GLP-1 receptors) that helps regulate your appetite and how much you eat and increases insulin production, 

decreasing the risk of stroke, heart attack, and other diseases by regulating blood sugar levels and blood pressure in those affected by obesity and/or type 2 diabetes. Semaglutide is offered in the following five dosages: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg. 

The starting dose is 0.25 mg injected once weekly for 4 weeks. After that, your dose may be increased every 4 weeks, allowing your body to adjust and get used to the medication until you reach the maximum maintenance dose of 2.4 mg once weekly, where you will experience the most weight loss and effects. Depending on the severity of side effects and how you’re tolerating the medication, the provider may change the dosage.

Tirzepatide

Tirzepatide is also a once-weekly self-injectable medication that has shown up to a 22.5% reduction in total body weight. Tirzepatide is the active ingredient in Mounjaro, an FDA-approved medication for the treatment of diabetes, being used off-label for the treatment of obesity and weight loss. Tirzepatide is expected to receive FDA approval for weight loss in the next year. Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist. Studies have shown it to yield a 50% greater weight loss than semaglutide and a greater reduction in appetite and blood sugar levels. 

Tirzepatide also delays gastric emptying, increasing the feelings of fullness and satiety. It is offered in the following six dosages: a 2.5 mg starting dose, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The starting dose is 2.5 mg injected once weekly for 4 weeks. Similar to semaglutide, your dose may be increased every 4 weeks, allowing your body to gradually adjust and get used to the medication until you reach the maximum maintenance dose of 15 mg once weekly. Depending on the severity of side effects and how you’re tolerating the medication, the provider may change the dosage.

Patients who are pregnant, planning to become pregnant, breastfeeding, diagnosed with type 1 diabetes, have impaired kidney function, have a history of pancreatitis, low blood sugar, or have a history or diagnosis of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN II) are not eligible candidates for semaglutide or tirzepatide. Medications that may affect the dosage or outcome of semaglutide/tirzepatide medication include chloroquine, hydroxychloroquine, and venlafaxine. It is important to let your provider know all current medications and your medical history.

Are you pregnant, planning to become pregnant, or breastfeeding?

Have you been diagnosed with type 1 diabetes?

Do you have impaired kidney function or have a history of pancreatitis?

Do you have low blood sugar?

Do you have a history or diagnosis of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN II)?

10 + 12 =

Semaglutide

Semaglutide is a self-injectable weight loss medication that can support long-term weight management. Semaglutide is the active ingredient in the brand name drugs Ozempic and Wegovy. It is the first weight management drug for adults that has been FDA-approved since 2017 for long-term weight loss. With a once-weekly subcutaneous injection (under the skin), you can experience a decrease in appetite, reduced cravings, and an increase in fullness/satiety. Researchers found that the average weight loss is 15% of the total body weight. Semaglutide does this by targeting an area in the brain (called GLP-1 receptors) that helps regulate your appetite and how much you eat and increases insulin production, 

decreasing the risk of stroke, heart attack, and other diseases by regulating blood sugar levels and blood pressure in those affected by obesity and/or type 2 diabetes. Semaglutide is offered in the following five dosages: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg. 

The starting dose is 0.25 mg injected once weekly for 4 weeks. After that, your dose may be increased every 4 weeks, allowing your body to adjust and get used to the medication until you reach the maximum maintenance dose of 2.4 mg once weekly, where you will experience the most weight loss and effects. Depending on the severity of side effects and how you’re tolerating the medication, the provider may change the dosage.

Tirzepatide

Tirzepatide is also a once-weekly self-injectable medication that has shown up to a 22.5% reduction in total body weight. Tirzepatide is the active ingredient in Mounjaro, an FDA-approved medication for the treatment of diabetes, being used off-label for the treatment of obesity and weight loss. Tirzepatide is expected to receive FDA approval for weight loss in the next year. Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist. Studies have shown it to yield a 50% greater weight loss than semaglutide and a greater reduction in appetite and blood sugar levels. 

Tirzepatide also delays gastric emptying, increasing the feelings of fullness and satiety. It is offered in the following six dosages: a 2.5-mg starting dose, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The starting dose is 2.5 mg injected once weekly for 4 weeks. Similar to semaglutide, your dose may be increased every 4 weeks, allowing your body to gradually adjust and get used to the medication until you reach the maximum maintenance dose of 15 mg once weekly. Depending on the severity of side effects and how you’re tolerating the medication, the provider may change the dosage.

Patients who are pregnant, planning to become pregnant, breastfeeding, diagnosed with type 1 diabetes, have impaired kidney function, have a history of pancreatitis, low blood sugar, or have a history or diagnosis of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN II) are not eligible candidates for semaglutide or tirzepatide. Medications that may affect the dosage or outcome of semaglutide/tirzepatide medication include chloroquine, hydroxychloroquine, and venlafaxine. It is important to let your provider know all current medications and your medical history.